N/A N=160 Patient-Centered Care for the Older Adult With Hematologic Malignancy
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=202 Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Phase 2 N=62 Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Phase 2 N=41 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Phase 2 N=20 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Overall Response Rate — 12; 1; 7 Participants
N/A N=18 Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Phase 2 N=4 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Phase 2 N=34 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Phase 2 N=89 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Phase 2 N=142 Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) — 49; 10 Participants
Phase 2 N=16 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Phase 2 N=27 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Acute Myelocytic Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…
Phase 2 N=2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
Sickle Cell Anemia · Severe Aplastic Anemia · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Patients With Neutrophil Engraftment — 2 participants
Phase 2 N=34 Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Phase 2 N=31 Stem Cell Transplantation for Patients With Cancers of the Blood
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
N/A N=41 An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
Hematologic Malignancies
Primary: Retention Rate — 38; 3 Participants
Phase 2 N=20 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Incidence of Graft Rejection for Patients at Day 100 — 0 participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
N/A N=10 AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB) — 100; 100; 100 percentage of surviving patients
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
N/A N=30 Exercise Prehab in Older Adults With Hematologic Malignancies
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants
Phase 2 N=5 Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Transplantation-related Mortality at 100 Days Post-transplantation — 2 Participants
N/A N=39 Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Phase 2 N=116 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=52 Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
N/A N=66 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Treatment-related Mortality Within the First 6 Months After Transplantation — 6 participants
Phase 3 N=551 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Phase 2 N=34 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants